HCM : Phase III Study Of Savolitinib Combo Shows Promising Results For EGFR-Mutated NSCLC Treatment

HUTCHMED's Phase III SACHI study revealed that the savolitinib and osimertinib combination significantly improved progression-free survival (PFS) in EGFR mutation-positive NSCLC patients with MET amplification, demonstrating an investigator-assessed median PFS of 8.2 months compared to 4.5 months with chemotherapy. The combination therapy also showed a higher objective response rate (ORR) of 58% versus 34% for chemotherapy, with a manageable safety profile, suggesting a potential new oral treatment option for patients who have progressed on prior EGFR inhibitor therapy. Overall survival data was not yet mature at the time of the interim analysis.

Analysis

HUTCHMED (China) Limited's SACHI Phase III study results indicate a significant clinical advancement for treating EGFR mutation-positive non-small cell lung cancer (NSCLC) with MET amplification in patients who have progressed on prior EGFR inhibitor therapy. The combination of savolitinib and osimertinib demonstrated markedly improved efficacy over chemotherapy, with an investigator-assessed median progression-free survival (PFS) of 8.2 months versus 4.5 months for chemotherapy, and an Independent Review Committee (IRC) assessed median PFS of 7.2 months versus 4.2 months. Furthermore, the combination achieved a superior objective response rate (ORR) of 58% compared to 34% with chemotherapy, a disease control rate (DCR) of 89% versus 67%, and a median duration of response (DoR) of 8.4 months versus 3.2 months. Notably, these benefits were achieved with a tolerable safety profile, as Grade 3 or above treatment-emergent adverse events occurred in 57% of patients in both the combination and chemotherapy arms, with no new safety signals observed for the savolitinib plus osimertinib regimen. While overall survival data is not yet mature, these interim findings highlight the potential for this novel, chemotherapy-free oral combination to address a critical unmet medical need, offering a convenient and well-tolerated treatment option. The "strongly positive" sentiment (0.85 score) and high market impact score (0.75) underscore the perceived significance of these results.

Key Decisions for Investors

• The compelling efficacy and safety data from the SACHI Phase III study substantially de-risks the savolitinib and osimertinib combination, potentially positioning it as a new standard of care and a significant value driver for HUTCHMED in this specific NSCLC patient population.
• Investors should closely monitor forthcoming catalysts, particularly the maturation of overall survival data, subsequent regulatory submissions, and potential approvals, which will be pivotal for the combination's commercial prospects and market penetration.
• Given the robust clinical outcomes and positive market signals, consider the potential for upward revaluation of HUTCHMED (HCM), while also assessing the competitive landscape and the company's ability to successfully commercialize this asset if approved.